pentoxifylline has been researched along with Body Weight in 32 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pentoxifylline (PTX) is a candidate for adjunct immunomodulatory therapy in preterm infants with late-onset sepsis (LOS) and necrotizing enterocolitis (NEC), but pharmacokinetic data in this population are extremely limited." | 9.30 | Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes. ( Batty, KT; Doherty, DA; Hibbert, J; Manning, L; Page-Sharp, M; Patole, S; Salman, S; Simmer, K; Strunk, T, 2019) |
| "Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicity of this drug in patients with cancer-associated anorexia and/or cachexia." | 9.08 | Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. ( Chong, SF; Ghosh, C; Goldberg, RM; Hestorff, RD; Krook, JE; Loprinzi, CL; Mailliard, JA; O'Fallon, JR; Reuter, NF; Shanahan, TG, 1995) |
| "Cardiac inflammation was interrogated via expression levels of TNF α, interleukins 6 and 10, phosphorylated STAT4 and lipoxygenases 12 and 12/15." | 5.62 | Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway. ( Abdelzaher, LA; Ali, M; Bakr, MH; Desai, AA; Mali, V; Radwan, E; Sayed, SA, 2021) |
| "Cardiac cachexia was rapidly induced with monocrotaline in Sprague-Dawley rats." | 5.35 | Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. ( Booth, FW; Lees, SJ; Steffen, BT, 2008) |
| "Pentoxifylline (PTX) is an inhibitor of cytokines and PAF and would reduce the generation of ROS by granulocytes and endothelial cells." | 5.34 | Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. ( Lee, P; Prasad, K, 2007) |
| " Pentoxifylline (PTX) is a candidate for adjunct immunomodulatory therapy in preterm infants with late-onset sepsis (LOS) and necrotizing enterocolitis (NEC), but pharmacokinetic data in this population are extremely limited." | 5.30 | Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes. ( Batty, KT; Doherty, DA; Hibbert, J; Manning, L; Page-Sharp, M; Patole, S; Salman, S; Simmer, K; Strunk, T, 2019) |
| "Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicity of this drug in patients with cancer-associated anorexia and/or cachexia." | 5.08 | Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. ( Chong, SF; Ghosh, C; Goldberg, RM; Hestorff, RD; Krook, JE; Loprinzi, CL; Mailliard, JA; O'Fallon, JR; Reuter, NF; Shanahan, TG, 1995) |
| " We hypothesized that myriocin (MYR), an inhibitor of de novo ceramide synthesis, would protect against glucose intolerance in saturated fat-fed mice, while lisofylline (LSF), a functional inhibitor of PA synthesis, would protect unsaturated fat-fed mice." | 3.76 | Saturated- and n-6 polyunsaturated-fat diets each induce ceramide accumulation in mouse skeletal muscle: reversal and improvement of glucose tolerance by lipid metabolism inhibitors. ( Frangioudakis, G; Garrard, J; Mitchell, TW; Nadler, JL; Raddatz, K; Schmitz-Peiffer, C, 2010) |
| " The aim of this study was to determine the adverse effects of maternal nicotine exposure during pregnancy and lactation on neonatal rat bone development, and to determine a protective effect of pentoxifylline (PTX)." | 3.74 | Influence of maternal nicotine exposure on neonatal rat bone: protective effect of pentoxifylline. ( Bastug, F; Bastug, O; Canoz, O; Gunes, I; Gunes, T; Koklu, E; Kula, M; Kurtoglu, S, 2007) |
| " The present study compares the effects of the cGMP production-increasing soluble guanylate cyclase (sGC) stimulator BAY 41-2272 with those of the cGMP degradation-limiting phosphodiesterase inhibitor pentoxifylline (PTX) in a progressive model of renal fibrosis." | 3.73 | Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. ( Kawachi, H; Krämer, S; Kron, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Shimizu, F; Wang, Y, 2006) |
| "The purposes of this study were to determine the tumor necrosis factor (TNF) and interleukin-6 (IL-6) levels after the induction of acute necrotizing pancreatitis, and to establish the effects of pentoxifylline on cytokine production." | 3.70 | Beneficial effects of pentoxifylline treatment of experimental acute pancreatitis in rats. ( Balogh, A; Farkas, G; Jarmay, K; Lonovics, J; Marton, J; Nagy, Z; Szasz, Z; Takacs, T; Varga, J, 1998) |
| " With human bladder cancer cells in culture, cytotoxicity of thiotepa was increased up to 10-fold (P less than 0." | 3.67 | In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa. ( Alley, MC; Chen, ZY; Fingert, HJ; Googe, PB; Pardee, AB; Pu, AT, 1988) |
| "Pentoxifylline, a new xanthine derivative with properties favorably affecting the rheological profile of blood, was administered to male rats weighing 200--300 g in doses of 5, 10, 15, and 20 mg/kg of body weight for five days." | 3.66 | Inhibition cAMP-phosphodiesterase in the rat heart by pentoxifylline--a new xanthine derivative. ( Deo, S; Nair, KG; Nandi, JS, 1980) |
| "Since an AIDS Clinical Trial Group study suggested that pentoxifylline (400 mg thrice daily) is safe in AIDS patients and decreases TNF mRNA levels in peripheral blood mononuclear cells (PBMC), a second cohort received 800 mg thrice daily for 8 weeks." | 2.68 | High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. ( Ahlers, CM; Chapman, B; Dando, S; Dezube, BJ; Flexner, C; Korvick, JA; Lederman, MM; Mattiacci, MR; Spritzler, JG; Zhang, L, 1995) |
| "Cancer anorexia and cachexia are two distinct syndromes which may have synergistic effects in a patient." | 2.41 | [Tumour anorexia--tumour cachexia in case of gastrointestinal tumours: standards and visions]. ( Gastell, S; Lochs, H; Ockenga, J; Pirlich, M, 2002) |
| "Cardiac inflammation was interrogated via expression levels of TNF α, interleukins 6 and 10, phosphorylated STAT4 and lipoxygenases 12 and 12/15." | 1.62 | Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway. ( Abdelzaher, LA; Ali, M; Bakr, MH; Desai, AA; Mali, V; Radwan, E; Sayed, SA, 2021) |
| " We investigated the effect of chronic administration (2 weeks) of imipramine (20 mg/kg/day) and pentoxifylline (50 mg/kg/day) on behavioral, aortic histological abnormalities, and level of circulating endothelial progenitor cells (CEPCs) in peripheral blood of male Wistar rats exposed to chronic mild stress (CMS) and high-fat diet." | 1.51 | Pentoxifylline ameliorates chronic stress/high-fat diet-induced vascular wall disease: the role of circulating endothelial progenitor cells. ( Abdel-Tawab, AM; Aboul-Fotouh, S; Farrag, KA; Habib, MZ; Labib, JMW; Mekawy, MAEA, 2019) |
| "Cardiac cachexia was rapidly induced with monocrotaline in Sprague-Dawley rats." | 1.35 | Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. ( Booth, FW; Lees, SJ; Steffen, BT, 2008) |
| "Pentoxifylline (PTX) is an inhibitor of cytokines and PAF and would reduce the generation of ROS by granulocytes and endothelial cells." | 1.34 | Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. ( Lee, P; Prasad, K, 2007) |
| "Pentoxifylline co-treatment attenuated this decrease compared with GFR in the CsA alone group (13." | 1.30 | Beneficial effects of pentoxifylline on cyclosporine-induced nephrotoxicity. ( Boz, A; Kaputlu, I; Karayalçin, B; Sadan, G, 1997) |
| "Torbafylline treatment had little further effect on ischemic muscles subjected to mild stimulation, which on its own improved functional hyperemia, resistance to fatigue, and the capillaries per fibre ratio in tibialis anterior, although it did significantly increase the capillary per fibre ratio in extensor digitorum longus." | 1.29 | Effect of torbafylline on muscle blood flow, performance, and capillary supply in ischemic muscles subjected to varying levels of activity. ( Brown, MD; Egginton, S; Hudlicka, O; Okyayuz-Baklouti, I, 1994) |
| " According to the limiting index of LD50 with, Oral dose of (1220 mg/kg of body mass for male rats and 1050 mg/kg for female rats) and intraperitoneal PP dose of PP (230 mg/kg for female rats and 235 mg/kg for female rats) it was included into IV class of slightly toxic compounds." | 1.28 | [Experimental research on the toxicity of pharmapentoxifylline (I)]. ( Donchev, N; Dzharova, V; Koleva, M; Udvareva, N, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (12.50) | 18.7374 |
| 1990's | 12 (37.50) | 18.2507 |
| 2000's | 10 (31.25) | 29.6817 |
| 2010's | 5 (15.63) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, M | 1 |
| Bakr, MH | 1 |
| Abdelzaher, LA | 1 |
| Sayed, SA | 1 |
| Mali, V | 1 |
| Desai, AA | 1 |
| Radwan, E | 1 |
| Arcaro, CA | 1 |
| Assis, RP | 1 |
| Zanon, NM | 1 |
| Paula-Gomes, S | 1 |
| Navegantes, LCC | 1 |
| Kettelhut, IC | 1 |
| Brunetti, IL | 1 |
| Baviera, AM | 1 |
| Salman, S | 1 |
| Hibbert, J | 1 |
| Page-Sharp, M | 1 |
| Manning, L | 1 |
| Simmer, K | 1 |
| Doherty, DA | 1 |
| Patole, S | 1 |
| Batty, KT | 1 |
| Strunk, T | 1 |
| Labib, JMW | 1 |
| Aboul-Fotouh, S | 1 |
| Habib, MZ | 1 |
| Mekawy, MAEA | 1 |
| Farrag, KA | 1 |
| Abdel-Tawab, AM | 1 |
| Menon, RT | 1 |
| Feferman, T | 1 |
| Aricha, R | 1 |
| Souroujon, MC | 1 |
| Fuchs, S | 1 |
| Steffen, BT | 1 |
| Lees, SJ | 1 |
| Booth, FW | 1 |
| Frangioudakis, G | 1 |
| Garrard, J | 1 |
| Raddatz, K | 1 |
| Nadler, JL | 2 |
| Mitchell, TW | 1 |
| Schmitz-Peiffer, C | 1 |
| Zaitone, S | 1 |
| Hassan, N | 1 |
| El-Orabi, N | 1 |
| El-Awady, el-S | 1 |
| Ockenga, J | 1 |
| Pirlich, M | 1 |
| Gastell, S | 1 |
| Lochs, H | 1 |
| Damron, TA | 1 |
| Spadaro, JA | 1 |
| Horton, JA | 1 |
| Margulies, BS | 1 |
| Strauss, JA | 1 |
| Farnum, CE | 1 |
| Wang, Y | 1 |
| Krämer, S | 1 |
| Loof, T | 1 |
| Martini, S | 1 |
| Kron, S | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Neumayer, HH | 1 |
| Peters, H | 1 |
| Pei, H | 1 |
| Gu, J | 1 |
| Thimmalapura, PR | 1 |
| Mison, A | 1 |
| Prasad, K | 1 |
| Lee, P | 1 |
| Kurtoglu, S | 1 |
| Gunes, T | 1 |
| Koklu, E | 1 |
| Bastug, O | 1 |
| Canoz, O | 1 |
| Kula, M | 1 |
| Bastug, F | 1 |
| Gunes, I | 1 |
| Nandi, JS | 1 |
| Nair, KG | 1 |
| Deo, S | 1 |
| Kocherezhkina, EV | 1 |
| Goldberg, RM | 1 |
| Loprinzi, CL | 1 |
| Mailliard, JA | 1 |
| O'Fallon, JR | 1 |
| Krook, JE | 1 |
| Ghosh, C | 1 |
| Hestorff, RD | 1 |
| Chong, SF | 1 |
| Reuter, NF | 1 |
| Shanahan, TG | 1 |
| Dezube, BJ | 2 |
| Lederman, MM | 1 |
| Spritzler, JG | 1 |
| Chapman, B | 2 |
| Korvick, JA | 2 |
| Flexner, C | 1 |
| Dando, S | 1 |
| Mattiacci, MR | 1 |
| Ahlers, CM | 2 |
| Zhang, L | 1 |
| Hudlicka, O | 2 |
| Egginton, S | 1 |
| Brown, MD | 1 |
| Okyayuz-Baklouti, I | 1 |
| Shibasaki, T | 1 |
| Nakano, H | 1 |
| Ohno, I | 1 |
| Ishimoto, F | 1 |
| Sakai, O | 1 |
| Pardee, AB | 2 |
| Beckett, LA | 1 |
| Novick, WJ | 1 |
| Chiurco, J | 1 |
| Kasdan, P | 1 |
| Ecto, LT | 1 |
| Kaputlu, I | 1 |
| Sadan, G | 1 |
| Karayalçin, B | 1 |
| Boz, A | 1 |
| Park, EJ | 1 |
| Ko, G | 1 |
| Kim, J | 1 |
| Sohn, DH | 1 |
| Frantz, RP | 1 |
| Edwards, BS | 1 |
| Olson, LJ | 1 |
| Schwab, MK | 1 |
| Adams, TF | 1 |
| Textor, SC | 1 |
| Daly, RC | 1 |
| McGregor, CG | 1 |
| Rodeheffer, RJ | 1 |
| Marton, J | 1 |
| Farkas, G | 1 |
| Takacs, T | 1 |
| Nagy, Z | 1 |
| Szasz, Z | 1 |
| Varga, J | 1 |
| Jarmay, K | 1 |
| Balogh, A | 1 |
| Lonovics, J | 1 |
| Entzian, P | 1 |
| Zähringer, U | 1 |
| Schlaak, M | 1 |
| Gerlach, C | 1 |
| Galle, J | 1 |
| Zabel, P | 1 |
| Juang, JH | 1 |
| Kuo, CH | 1 |
| Hsu, BR | 1 |
| Laurat, E | 1 |
| Poirier, B | 1 |
| Tupin, E | 1 |
| Caligiuri, G | 1 |
| Hansson, GK | 1 |
| Bariéty, J | 1 |
| Nicoletti, A | 1 |
| Koleva, M | 1 |
| Donchev, N | 1 |
| Udvareva, N | 1 |
| Dzharova, V | 1 |
| Price, S | 1 |
| Fingert, HJ | 1 |
| Pu, AT | 1 |
| Chen, ZY | 1 |
| Googe, PB | 1 |
| Alley, MC | 1 |
| Nemiroff, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS[NCT00000646] | Phase 1 | 54 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pentoxifylline and Body Weight
| Article | Year |
|---|---|
[Tumour anorexia--tumour cachexia in case of gastrointestinal tumours: standards and visions].
Topics: Adrenal Cortex Hormones; Algorithms; Anorexia; Body Weight; Cachexia; Cyclooxygenase Inhibitors; Die | 2002 |
4 trials available for pentoxifylline and Body Weight
| Article | Year |
|---|---|
Effects of maturation and size on population pharmacokinetics of pentoxifylline and its metabolites in very preterm infants with suspected late-onset sepsis or necrotizing enterocolitis: a pilot study incorporating clinical outcomes.
Topics: Administration, Intravenous; Body Weight; Drug Therapy, Combination; Enterocolitis, Necrotizing; Fem | 2019 |
Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.
Topics: Aged; Anorexia; Appetite; Body Weight; Cachexia; Double-Blind Method; Female; Humans; Male; Middle A | 1995 |
High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; beta 2-Microglobulin; Biopterins; Body Weight; CD4 Lymphocyte Co | 1995 |
Effects of pentoxifylline on renal function and blood pressure in cardiac transplant recipients: a randomized trial.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Weight; Cyclosporine; Doubl | 1997 |
27 other studies available for pentoxifylline and Body Weight
| Article | Year |
|---|---|
Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Apoptosis; Blood Glucose; Body Weight; Disea | 2021 |
Involvement of cAMP/EPAC/Akt signaling in the antiproteolytic effects of pentoxifylline on skeletal muscles of diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Cyclic AMP; Diabetes Mellitus, Experimental; Drug Evaluation, P | 2018 |
Pentoxifylline ameliorates chronic stress/high-fat diet-induced vascular wall disease: the role of circulating endothelial progenitor cells.
Topics: AC133 Antigen; Animals; Aorta, Thoracic; Body Weight; Chronic Disease; Diet, High-Fat; Endothelial P | 2019 |
Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent.
Topics: Animals; Antibodies; Body Weight; Cytokines; Disease Models, Animal; Dose-Response Relationship, Dru | 2008 |
Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia.
Topics: Animals; Anorexia; Blotting, Western; Body Weight; Cachexia; Eating; Enzyme-Linked Immunosorbent Ass | 2008 |
Saturated- and n-6 polyunsaturated-fat diets each induce ceramide accumulation in mouse skeletal muscle: reversal and improvement of glucose tolerance by lipid metabolism inhibitors.
Topics: Animals; Blood Glucose; Body Weight; Cell Line; Ceramides; Dietary Fats; Fatty Acids; Fatty Acids, M | 2010 |
Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Biomarkers; Body Weight; C | 2011 |
Combinations of radioprotectants spare radiation-induced damage to the physis.
Topics: Amifostine; Animals; Body Weight; Bone Density; Bone Development; Drug Therapy, Combination; Femur; | 2004 |
Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition.
Topics: Animals; Blood Pressure; Body Weight; Cell Proliferation; Cyclic GMP; Drinking; Fibrosis; Glomerulon | 2006 |
Activation of the 12-lipoxygenase and signal transducer and activator of transcription pathway during neointima formation in a model of the metabolic syndrome.
Topics: Angioplasty, Balloon; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 12-Lipoxygenase | 2006 |
Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism.
Topics: Animals; Antioxidants; Aorta; Atherosclerosis; Body Weight; Butylene Glycols; Cholesterol, Dietary; | 2007 |
Influence of maternal nicotine exposure on neonatal rat bone: protective effect of pentoxifylline.
Topics: Animals; Animals, Newborn; Animals, Suckling; Apoptosis; Birth Weight; Body Weight; Bone and Bones; | 2007 |
Inhibition cAMP-phosphodiesterase in the rat heart by pentoxifylline--a new xanthine derivative.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Body Weight; Dose-Response Relationship, Drug; Heart; | 1980 |
[Changes in body weight and skeletal muscles in hypokinetic animals].
Topics: Animals; Body Weight; Male; Muscles; Pentoxifylline; Rats; Restraint, Physical; Time Factors | 1982 |
Effect of torbafylline on muscle blood flow, performance, and capillary supply in ischemic muscles subjected to varying levels of activity.
Topics: Animals; Body Weight; Capillaries; Electric Stimulation; Electrodes, Implanted; Ischemia; Isometric | 1994 |
Effect of pentoxifylline on CdCl2-induced nephrotoxicity in the rat.
Topics: Acetylglucosaminidase; Animals; Body Weight; Cadmium; Cadmium Chloride; Chlorides; Kidney; Male; Pen | 1994 |
Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; beta 2-Microglobulin; Biopterins; Body Weight; CD4-Positi | 1993 |
Beneficial effects of pentoxifylline on cyclosporine-induced nephrotoxicity.
Topics: Animals; Blood Pressure; Body Weight; Creatinine; Cyclosporine; Heart Rate; Immunosuppressive Agents | 1997 |
Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction.
Topics: Animals; Basidiomycota; Body Weight; Cholestasis; Common Bile Duct Diseases; Female; Glycyrrhetinic | 1997 |
Beneficial effects of pentoxifylline treatment of experimental acute pancreatitis in rats.
Topics: Acute Disease; Animals; Body Weight; Interleukin-6; Male; Organ Size; Pancreatitis, Acute Necrotizin | 1998 |
Comparative study on effects of pentoxifylline, prednisolone and colchicine in experimental alveolitis.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Body Weight; Bronchoalveolar Lavage Fluid | 1998 |
Beneficial effects of pentoxiphylline on islet transplantation.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Insulin; Islets of Langerhans; | 2000 |
In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Body Weight; Cell Count; Cell Differentiation; Cells, | 2001 |
[Experimental research on the toxicity of pharmapentoxifylline (I)].
Topics: Animals; Blood Cells; Body Weight; Dose-Response Relationship, Drug; Female; Lethal Dose 50; Male; P | 1990 |
Effects of torbafylline, pentoxifylline and buflomedil on vascularisation and fibre type of rat skeletal muscles subjected to limited blood supply.
Topics: Animals; Blood Pressure; Body Weight; Capillaries; In Vitro Techniques; Male; Muscle Contraction; Mu | 1990 |
In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cells, Cultured; Drug Synergis | 1988 |
Synergistic effects of pentoxifylline and hyperbaric oxygen on skin flaps.
Topics: Animals; Body Weight; Drug Synergism; Graft Survival; Hyperbaric Oxygenation; Male; Pentoxifylline; | 1988 |